Impact of Omicron on Lung Transplant Recipients: A Third COVID-19 Surge with Different Outcomes

Hum, Jamie; Laothamatas, Kemarut; Scheffert, Jenna; Nolan, Margaret; Reilly, Genevieve; D’Ovidio, Frank; Benvenuto, Luke; Arcasoy, Selim M.

doi:10.1513/annalsats.202205-452rl

Cited by 6 publications

(6 citation statements)

References 9 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[16][17][18][19][20] In a previous study performed during the prevalence of the omicron variant, hospitalization (40%) and mortality (12%) rates were also higher than in the present study. 9 Age, Charlson Comorbidity Index, and obesity were found to be associated with both the primary and secondary outcomes, with age >60 years being independently associated with hospitalization for COVID-19 symptoms; this is in line with previous studies. 17,19 We found a beneficial role of mAbs in LTR, which is in accordance with literature.…”

Section: Discussionsupporting

confidence: 90%

“…Another explanation could be that all LTRs were instructed to contact the transplantation center in case of COVID‐19‐compatible symptoms and following a positive antigenic test or PCR for SARS‐CoV‐2 irrespective of the severity of symptoms, leading to a higher inclusion of outpatients as compared to previous studies 16–20 . In a previous study performed during the prevalence of the omicron variant, hospitalization (40%) and mortality (12%) rates were also higher than in the present study 9 …”

Section: Discussioncontrasting

confidence: 62%

“…As the pandemic evolved, the improvement of management by anti‐SARS‐CoV‐2‐specific (anti‐spike monoclonal antibodies [mAbs], antivirals) and non‐specific (corticosteroids, tocilizumab) treatments together with vaccination has led to a decrease in overall mortality 6–8 . However, there are limited data of the impact of antiviral therapy, vaccination, and SARS‐CoV‐2 variants on the clinical evolution of COVID‐19 specifically in LTRs 4,6,9 …”

Section: Introductionmentioning

confidence: 99%

“…SARS-CoV-2 variants on the clinical evolution of COVID-19 specifically in LTRs. 4,6,9 In this study, we aim to describe the outcomes of SARS-CoV-2 infection in LTR and identify predictors of poor outcome.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Outcomes of SARS‐CoV‐2 infection among lung transplant recipients: A single center retrospective study

Casutt

Papadimitriou-Olivgeris

Ioakeim

et al. 2023

Transplant Infectious Dis

View full text Add to dashboard Cite

Background: Lung transplant recipients (LTRs) are at increased risk for coronavirus disease 2019 (COVID-19)-associated complications. Methods:We aimed to describe the outcomes of polymerase chain reactiondocumented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in LTRs followed at our institution from March 2020 to July 2022. The primary outcome investigated was hospitalization or death from COVID-19-related symptoms within 28 days from diagnosis.Results: Overall, 60 cases were included, of which 18 (30%) reached the primary outcome. Only one patient (2%) died. Anti-spike monoclonal antibodies (mAbs) were administered as early treatment in 36 patients (casirivimab/imdevimab = 2, sotrovimab = 31, and tixagevimab/cilgavimab = 3). Multivariate analysis revealed that age >60 years (p = .003; odds ratio [OR] 9.41; confidence interval [CI] 2.52-41.05) was associated with a higher risk for the primary outcome, while administration of mAbs as early treatment (p = .030; OR 0.23; CI 0.06-0.87) was associated with a lower risk.No effect of vaccination and SARS-CoV-2 variant was observed. Forced expiratory volume in 1 s and forced vital capacity values did not decrease among 37 patients who had spirometry performed 1 month after COVID-19. Conclusions:We observed a relatively low morbidity and mortality of COVID-19 in LTR. mAb administration was associated with a better outcome.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussioncontrasting

confidence: 62%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Outcomes of SARS‐CoV‐2 infection among lung transplant recipients: A single center retrospective study

Casutt

Papadimitriou-Olivgeris

Ioakeim

et al. 2023

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…Previous publications have shown mortality rates of 25%-34% in LTR during the wild-type and Delta variant eras [3], while Hum et al reported a mortality rate of 12% specifically in Omicron variant era [31]. This would suggest, despite higher transmissibility in the Omicron variant widely reported in the literature, the virulence appeared lower.…”

Section: Viral Variant Erasmentioning

confidence: 86%

Low Mortality Associated with COVID-19 Infection in Lung Transplant Recipients at a Single Center

Gomez,

Kafi,

Yung

et al. 2024

OBM Transplant

View full text Add to dashboard Cite

Lung Transplant Recipients (LTR) are particularly vulnerable to severe infection, hospitalization, and death due to community acquired respiratory viruses. As a result, the global SARS-Cov-2 pandemic poses a higher risk to this population. We aim to study the lung function, severity of infection and mortality among LTR at a single center. A retrospective chart review was performed on all LTR at the University of San Diego, California Medical Center between June 2020 and September 2022. Spirometry was performed at 1-2 months and then again 3 months after infection. Patients were closely monitored for the development of acute cellular rejection (ACR). 72 LTR were infected with COVID-19. 37.5% required hospital admission, of which 25.9% required management in the intensive care unit (ICU). 73.6% LTR had received at least one vaccination dose prior to infection. Post-infection, the median drop in FEV1 was 140 mL and FVC was 25 mL within 1-2 months. At 3 months post-infection the median reduction in FVC was slightly larger at 75 ml, while median decline in FEV1 decreased to 55 ml. Overall, the rates of ACR and mortality in this population were both 4.2%. Additionally, monoclonal antibody (mAb) therapy reduced hospitalization (20.9% vs 62%) and mortality (0% vs 10.3%), Our study found low rates of ACR and mortality in LTR with confirmed COVID-19, despite the statistically significant decline in FEV1, and trends with FVC. The use of vaccinations and mAb therapy decreased rates of hospitalizations, with mAb therapy reducing mortality as well.

show abstract

COVID-19 infection is mild and has minimal impact on lung function in well vaccinated and widely treated lung transplant recipients

Ennis,

Levvey,

Shingles

et al. 2024

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Impact of Omicron on Lung Transplant Recipients: A Third COVID-19 Surge with Different Outcomes

Cited by 6 publications

References 9 publications

Outcomes of SARS‐CoV‐2 infection among lung transplant recipients: A single center retrospective study

Outcomes of SARS‐CoV‐2 infection among lung transplant recipients: A single center retrospective study

Low Mortality Associated with COVID-19 Infection in Lung Transplant Recipients at a Single Center

COVID-19 infection is mild and has minimal impact on lung function in well vaccinated and widely treated lung transplant recipients

Contact Info

Product

Resources

About